Flibanserin

Brand names: Addyi · Active ingredient: Flibanserin

In short: ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: • A co-existing medical or psychiatric conditio

Forms & strengthsTablets: 100 mg, oval, pink, debossed on one side with "f100" and blank on the other side.
LabelSprout Pharmaceuticals, Inc.
Label updatedDec 23, 2025

What is Flibanserin used for?

ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to:

•

A co-existing medical or psychiatric condition,

•

Problems within the relationship, or

•

The effects of a medication or other drug substance.

Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.

Limitations of Use

•

ADDYI is not indicated in men.

•

ADDYI is not indicated to enhance sexual performance.

⚠ Boxed warning (FDA's strongest warning)

Interaction with Alcohol

The use of ADDYI and alcohol together close in time increases the risk of severe hypotension and syncope . Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more standard alcoholic drinks that evening.

Contraindicated with Strong or Moderate CYP3A4 Inhibitors

The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope . Therefore, the use of moderate or strong CYP3A4 inhibitors is contraindicated in patients taking ADDYI .

Contraindicated in Patients with Hepatic Impairment

The use of ADDYI in patients with hepatic impairment increases flibanserin concentrations, which can cause severe hypotension and syncope . Therefore, ADDYI is contraindicated in patients with hepatic impairment .

Flibanserin dosage

The recommended dosage of ADDYI is 100 mg administered orally once per day at bedtime. ADDYI is dosed at bedtime because administration during waking hours increases the risks of hypotension, syncope, accidental injury, and central nervous system (CNS) depression (such as somnolence and sedation).

If a dose of ADDYI is missed at bedtime, instruct the patient to take the next dose at bedtime on the next day. Instruct the patient to not double the next dose.

Discontinue ADDYI after 8 weeks if the patient does not report an improvement in her HSDD symptoms.

If initiating ADDYI following moderate or strong CYP3A4 inhibitor use, start ADDYI 2 weeks after the last dose of the CYP3A4 inhibitor.

If initiating a moderate or strong CYP3A4 inhibitor following ADDYI use, start the moderate or strong CYP3A4 inhibitor 2 days after the last dose of ADDYI .

How to take Flibanserin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Hypotension and Syncope

Inform patients that ADDYI can cause severe hypotension and syncope, particularly when taken close in time with alcoholic drinks or with moderate or strong CYP3A4 inhibitors.

•Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed 3 or more standard alcoholic drinks that evening.After taking ADDYI at bedtime, advise patients to not use alcohol until the following day.

•Advise patients that moderate or strong CYP3A4 inhibitors are contraindicated with ADDYI and to ask patients to report the use of a new prescription or non-prescription medication or other products that contain CYP3A4 inhibitors (e.g., grapefruit juice, St. John’s Wort).

•Advise patients who experience pre-syncope or lightheadedness to lie down and to call for help if symptoms persist . …

Warnings & precautions

Do not take this medicine if: ADDYI is contraindicated in patients:

•Using concomitant moderate or strong CYP3A4 inhibitors .

•With hepatic impairment .

•With known hypersensitivity to ADDYI or any of its components. Reactions, including anaphylaxis, reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth), pruritus, and urticaria have been reported .

Taking ADDYI within two hours after consuming alcohol increases the risk of severe hypotension and syncope. To reduce this risk, counsel patients to wait at least two hours after drinking one or two standard alcoholic drinks before taking ADDYI at bedtime . Patients who drink three or more standard alcoholic drinks should skip their ADDYI dose that evening. One standard alcoholic drink contains 14 grams of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).

After taking ADDYI at bedtime, advise patients to not use alcohol until the following day.

Moderate or Strong CYP3A4 Inhibitors

The concomitant use of ADDYI with moderate or strong CYP3A4 inhibitors significantly increases flibanserin concentrations, which can lead to hypotension and syncope . The concomitant use of ADDYI with a moderate or strong CYP3A4 inhibitor is contraindicated. If the patient requires a moderate or strong CYP3A4 inhibitor, discontinue ADDYI at least 2 days prior to starting the moderate or strong CYP3A4 inhibitor. In cases where the benefit of initiating a moderate or strong CYP3A4 inhibitor within 2 days of stopping ADDYI clearly outweighs the risk of flibanserin exposure related hypotension and syncope, monitor the patient for signs of hypotension and syncope. Discontinue the moderate or strong CYP3A4 inhibitor for 2 weeks before restarting ADDYI . …

Flibanserin side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

•Hypotension and syncope

•CNS depression

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The approved 100 mg ADDYI dosage at bedtime was administered to 2,997 premenopausal women with acquired, generalized HSDD in clinical trials, of whom 1,672 received treatment for at least 6 months, 850 received treatment for at least 12 months, and 88 received treatment for at least 18 months .

In clinical trials, ADDYI 100 mg once daily at bedtime was administered to 801 postmenopausal women less than 65 years of age with acquired, generalized HSDD, of whom 460 received ADDYI treatment for at least 6 months, and 23 received ADDYI treatment for longer than 6 months.

Premenopausal Women

The data presented below in

Table 1

and

Table 2

(left columns) are derived from five 24-week randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD. In these trials, the frequency and quantity of alcohol use was not recorded. Three of these trials (Studies 1, 2, and 3) also provided efficacy data . One trial (Study 5) did not evaluate the 100 mg bedtime dose. …

Drug interactions

Table 3 contains clinically significant drug interactions (DI) with ADDYI.

Alcohol

Clinical Implications | The coadministration of ADDYI with alcohol increased the risk of hypotension, syncope, and CNS depression compared to the use of ADDYI alone or alcohol alone .

Preventing or Managing DI | Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more alcoholic drinks that evening. .

Other CNS Depressants

Examples | Diphenhydramine, opioids, hypnotics, benzodiazepines

Clinical Implications | The concomitant use of ADDYI with CNS depressants may increase the risk of CNS depression (e.g., somnolence) compared to the use of ADDYI alone.

Preventing or Managing DI | Discuss the concomitant use of other CNS depressants with the patient when prescribing ADDYI. …

About this medicine

The chemical name of flibanserin is 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]. Its empirical formula is C20H21F3N4O and its molecular weight is 390.41.

The structural formula is:

Flibanserin is a white to off-white powder, insoluble in water, sparingly soluble in methanol, ethanol, acetonitrile and toluene, soluble in acetone, freely soluble in chloroform, and very soluble in methylene chloride.

ADDYI (flibanserin) tablets are for oral administration. Each ADDYI tablet contains 100 mg of flibanserin. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate, talc, macrogol, and the coloring agents, titanium dioxide and iron oxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3819daf3-e935-2c53-c527-e1d57922f394. Read the full official label on DailyMed.